Dissident AIDS Database

EpidemiologyNon sexual transmissionFactor VIII / hemophiliaAIDS
Use of CD4 lymphocyte count to predict long term survival free of AIDS after HIV infection.
 Phillips, A.N., C.A. Sabin, J. Elford, M. Bofill, G. Janossy & C.A. Lee
  Latent periods of over 20 years have been calculated for HIV-positive hemophiliacs based on the loss of T-cells over time.
  Br. Med. J. 309: 309-313. 19941994
Incidence of AIDS and excess mortality associated with HIV in haemophiliacs in the United Kingdom: report on behalf of the directors of haemophilia centers in the United Kingdom.
 Darby, S.C., C.R. Rizza, R. Doll, R.J.D. Spooner, I.M. Stratton & B. Thakrar,
  In the United Kingdom three percent of haemophilia patients developed AIDS by 3 years after seroconversion and 7% by 5 years post seroconversion
  Br. Med. J. 298: 1064-1068, 1989.1989
FOREIGN-PROTEIN-MEDIATED IMMUNODEFICIENCY IN HEMOPHILIACS WITH AND WITHOUT HIV
 Duesberg Peter
  The virus-AIDS hypothesis predicts that in 1994, at least one 10-year-latent-period after most American hemophiliacs were infected (hiv was eliminated from blood supply in 1984), over 50% of the 15,000 HIV-positive American hemophiliacs would have developed AIDS or died from AIDS (the number of aids death increasing annually until 1994). However, by the end of 1992, 2,214 American hemophiliacs with AIDS were reported to the CDC and since there are about 15,000 HIV-positive American hemophiliacs, an average of only 1.3% (201 out of 15,000) have developed AIDS annually between 1981 and 1992. After the inclusion of further diseases into the AIDS syndrome, and the introduction of AZT as an anti-HIV drug, both in 1987, the annual AIDS risk of American hemophiliacs appears to have stabilized at 2%, e.g. about 300 out of 15,000 per year until 1993 when the AIDS definition was changed again. The 1.3% to 2% annual AIDS risk indicates that the average HIV-positive hemophiliac would have to wait for 25 to 35 years to develop AIDS diseases from HIV. By contrast, the annual AIDS risk of the average, HIV-positive American in the mid-1990's was approximately 8%, because there were about 60,000 annual AIDS cases per 750 000 HIV-positive Americans, reflecting the annual AIDS-risks of the major risk groups, the male homosexuals and intravenous drug users making up about 93% of all American AIDS patients.Goedert et al, Risks of immunodeficiency, AIDS, and death related to purity of factor VIII concentrate (Multicenter Hemophilia Cohort Study, Lancet 1994 Sep 17;344(8925):791-2, CDC HIV/AIDS Surveillance; 1993, year-end edition. February: 1-23, Chorba et al, Changes in longevity and causes of death among persons with hemophilia, A. Am. J. Hematol. 45:112-121. 1994, Tsoukas et al, Association of HTLV-III antibodies and cellular immune status of hemophiliacs, N. Engl. J. Med. 31: 1514-1515, 1984, Hardy et al, The incidence rate of acquired immunodeficiency syndrome in selected populations, J. Am. Med. Assoc. 253: 215-220. 1985, Stehr-Green et al, Hemophilia-associated AIDS in the United States, 1981 to September 1987, Am. J. Public Health 78: 439-44. 1988, Sullivan et al, Hemophiliac immunodeficiency: influence of exposure to factor VIII concentrate, LAV/HTLV-III, and herpesviruses, J. Pediatr. 108: 504-510. 1986, Goedert et al, A prospective study of human immunodeficiency virus type 1 infection and the development of AIDS in subjects with hemophilia, N. Engl. J. Med. 321: 1141-1148. 1989, Koerper, M.A, AIDS and Hemophili, AIDS: Pathogenesis and Treatment, 1989. , pp. 79-95, J.A. Levy (ed.) Marcel Dekker, Inc., New York, Morgan et al, The future course of AIDS in the United States, J. Am. Med. Assoc. 263: 1539-1540, 1990, Gomperts et al, The Impact of Clotting Factor Concentrates on the Immune System in Individuals with Hemophilia, Transfus. Med. Rev. 6: 44-54, 1992, De Biasi et al, The impact of a very high purity of factor VIII concentrate on the immune system of human immunodcficiency virus-infected hemophiliacs: a randomized, prospective, two-year comparison with an intermediate purity concentrate, Blood 78: 1919-1922, 1991).
  Genetica 95: 51-70, 19951995
The incidence rate of acquired immunodeficiency syndrome in selected populations.
 Hardy, A.M., J.R. Allen, W.M. Morgan, and J.W. Curran,
  Hardy et al. from the CDC also noted the discrepancy in the latent periods of different risk groups. "The magnitude of some of the differences in rates is so great that even gross errors in denomination estimates can be overcome"
  J. Am. Med. Assoc. 253: 215-220. 1985.1985
A prospective study of human immunodeficiency virus type 1 infection and the development of AIDS in subjects with hemophilia.
 Goedert, J. J., Kessler, C. M., Aledort, L. M., Biggar, R. J., Abe Andes, W., White II, G. C., Drummond, J. E., Vaidya, K., Mann, D. L., Eyster, M. E., Ragni, M. V., Lederman, M. M., Cohen, A. R., Bray, G. L., Rosenberg, P. S., Friedman, R. M., Hilgartner, M. W., Blattner, W. A., Kroner, B. & Gail, M. H.,
  In a cohort of haemophiliacs, the annual incidence of AIDS ranged from zero during the first year after seroconversion to 7% during the eight year followup with an 8 year cummulative rate of 13.3%
  NEJM 321:1141-1148. 1989.1989
Acquired immunodeficiency syndrome among patients attending hemophilia treatment centers and mortality experience of hemophiliacs in the United States.
 Johnson, R.E., D.N. Lawrence, B.L. Evatt, D.J. Bregman, L.D. Zyla, J.W. Curran, L.M. Aledort, M.E. Eyster, A.P. Brownstein & C.J. Cannan
  "The number of deaths reported among factor VIII-deficient patients in the hemophilia treatment center survey decreased from 26 deaths and 24 deaths in 1978 and 1979, respectively, to 18 and 19 deaths in 1980 and 1981, respectively. The number of deaths then more than doubled, with 53 deaths reported for 1982. The two-to three-fold increase in deaths in 1982 include the first five reported of immunodeficiency, an increase in deaths assigned to haemorrhage unrelated to trauma, and an increase in deaths unrelated to AIDS or hemophilia. The sharp increase in deaths across all categories is most likely due to underreporting of deaths, as a result of hemophilia treatment centers inability to identify deaths in previous years"
  Am. J. Epidemiol. 121: 797-810, 19851985